In addition, in patients with metastatic CRPC, the presence of detectable AR-V7 transcripts in circulating tumor cells has been associated with a high positive predictive value for a non-response to AR-targeting agents, including enzalutamide, in several studies [45,46]. This evidence concerns the gene AR and neoplasm.